FranceSoir’s team have done some more excellent work in cutting through the dearth and making sense of some conflicting information.

Source: FranceSoir Authors: Michel Jullian and Xavier Azalbert (for FranceSoir)

Long discussions ignited the web and social networks on the role of hydroxychloroquine as a treatment against Covid-19. These exchanges often boil down to throwing in the face the results of various and varied studies. There followed an expert debate on the validity of the study and the various protocols, allowing each to be given the opportunity to advance, with a certain bad faith, their oriented arguments. Indeed, it is always possible to find an argument in favor of the result of a study if it tends to demonstrate the ineffectiveness of hydroxychloroquine, and vice versa.

When its effectiveness is not in question, we talk about its side effects. The reality is that this drug has been prescribed for 65 years (1955).  Its side effects and precautions for uses are well documented.

An almost incomprehensible debate for the French

It is becoming more and more difficult for viewers or readers to know where to turn, the debates of experts relating to points of detail so limited that we forget the essentials: there have been deaths, many too many dead and sick. While experts from a certain medical world disconnected from reality debated on television sets, other doctors were fighting with the disease without having the right to prescribe in their souls and conscience (according to the reasonably established state of science medical). The Lancet study will have caused great harm to patients since it was followed by immediate effects such as the suspension of prescription and dispensing authorizations for hydroxychloroquine. The World Health Organization (WHO)  decided to suspend the trials or to simply ban the drug from being dispensed. Switzerland did the same around the 27th of May, 2020.

The fraudulent study was withdrawn from the 4th of June, but Swiss patients remained deprived of this treatment until the 11th of June, “The OFSP decided to lift the measures put in place for its prescription and dispensing. The Plaquenil® and Zentiva® Hydroxychloroquine can be re-ordered directly from the wholesaler. ” According to the critics of hydroxychloroquine, these 15 days of prohibition should have had no impact on patient survival, but this is not the case: it is enough to look at the evolution over time of the proportion of deaths among newly resolved cases, only to find that hydroxychloroquine, the only molecule banned within this time, works.

Hydroxychloroquine saves lives.

It was enough the collaboration of three internet users to solve this enigma (see the article “story of a discovery”): the discovery of a strict temporary suspension of the HCQ in Switzerland, the nrCFR * efficiency index of treatments, the observation of a “bump” of ~ 2 weeks in this index for Switzerland, the link with the suspension, and finally the analysis concluding with the statistical significance of this correlation with a very high degree of certainty ( > 99%). All analyzes were made from international data “global time series” “Deaths” and “Recovered” from Johns Hopkins University updated every night.

Let’s take a look at the period when hydroxychloroquine was banned in Switzerland, i.e. from May 27th till June 11th, 2020. The27th of May is 5 days after the publication of the study criticized in The Lancet , which claimed to demonstrate the toxicity and ineffectiveness of hydroxychloroquine. The consequences of this publication had a global impact, leading to the suspension of hydroxychloroquine and thus depriving many patients of treatment. This ban on the pretext of “precaution” has surely done far more harm to patients than what our health ministers have said.

Looking at the evolution curve of this index for Switzerland, we note a “wave of excess lethality” of two weeks from June 9th to 22nd, with a lag of a dozen days compared to the period of suspension of the use of hydroxychloroquine by WHO. This demonstrates, without possible rebuttal, the effect of stopping the delivery and use of this drug in Switzerland (country which follows the recommendations of the WHO, based in Geneva). During the weeks preceding the ban, the nrCFR index fluctuated between 3% and 5%. Some 13 days after the start of the prohibition, the nrCFR index increases considerably to be between 10 and 15% for 2 weeks. Some 12 days after the end of the prohibition, the lethality falls back to a lower level.

We were looking for a signal, a proof, here it is the size of a country like Switzerland. Almost the size of the Ile-de-France (Paris area)

What arguments could the Minister of Health and experts in randomized controlled studies oppose to such glaring prosaically observational evidence?

The Lancet and the World Health Organization will have served a purpose. Thanks to them!

A statistically significant difference

For those who are not convinced of the observational result, we conducted a statistical difference test by comparing the three periods: May 28th – June 8th, June 9th – 22nd, June 23rd – July 6th . The period from June 9th till the 22nd is that in which the index increased some 13 days after the suspension of hydroxychloroquine. There is of course an effect of delay between stopping the prescription of the drug and possible deaths, which explains the delay of 13 days.

blank

We therefore observe that for the period from the 28th of May till the 8th of June, the index is 2.39% and then drops to 11.52% or 4.8 times more and then drops to 3%.

When testing for statistical significance between the various observations, the difference is significant at 99% with a p <0.0001. 13 days after the HCQ prescription was resumed, the index dropped to 3% and this was again a significant effect.

And for France

This index for France over the same period is found in the graph below. Note that during the prohibition period of hydroxychloroquine in Switzerland, the nrCFR index was almost identical between France and Switzerland.

blank

This important information should once and for all make everyone agree.

Editor’s note:

Thanks to Nathalie Izzo (@ Nathalienath19) and Annie Wypychowski.

the nrCFR index was created by Michel Jullian.

Translation: @Smackenziekerr & @PaulGreeff

Auteur(s): Michel Jullian and Xavier Azalbert for FranceSoir


Related: France 24: Hydroxychloroquine effective in treating COVID-19, according to study of 2,500

Bombshell: Media disinformation proven false as Henry Ford Health study finds Hydroxychloroquine lowers COVID-19 death rate.

Zelenko study: COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin; A Retrospective Case Series Study

Zelenko’s Protocol explained: over 2200 outpatients treated with 99.7% survival rate

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

Dr. Harvey Risch: Hydroxychloroquine, Ivermectin, and Other Therapeutics Highly Effective in Early COVID Treatment

I’ve railed against this in the media that we are a part of, and the way that the propaganda reacts to this is, “Ignore it. Ignore all of this.” I’m saying this now because the general public has to be the one that gets angry. The general public should be furious at the way people have been treated in the country by suppression of these drugs, by that kind of website that suppresses the ability of doctors to practice medicine.

Read More »

A Judge Stands up to a Hospital: “Step Aside” and Give a Dying Man Ivermectin

The judge’s finest moment may have been when he dashed the most glaring myth about ivermectin—that it is not safe, despite decades of use that shows otherwise. Noting that all drugs have side effects, Judge Fullerton listed ivermectin’s effects from a government website.
“(N)umber one, generally well tolerated; number two, dizziness; number three, pruritus; number four, nausea/diarrhea. These are the side effects for the dosage that’s being asked to be administered,” he said. “The risks of these side effects are so minimal that Mr. Ng’s current situation outweighs that risk by one-hundredfold.”

Read More »